Telmisartan prevents weight gain and obesity through activation of peroxisome proliferator-activated receptor-δ-dependent pathways

Hypertension

Volumn 55, Issue 4, 2010, Pages 869-879

  He, Hongbo ^a   Yang, Dachun ^a   Ma, Liqun ^a   Luo, Zhidan ^a   Ma, Shuangtao ^a   Feng, Xiaoli ^a   Cao, Tingbing ^a   Yan, Zhencheng ^a   Liu, Daoyan ^a   Tepel, Martin ^b   Zhu, Zhiming ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Adipogenesis; Energy uncoupling; Hormone sensitive lipase; Obesity; Peroxisome proliferator activated receptor ; Telmisartan

Indexed keywords

CANDESARTAN; CYCLIC AMP DEPENDENT PROTEIN KINASE; LOSARTAN; PERILIPIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TELMISARTAN; TRIACYLGLYCEROL LIPASE; UNCOUPLING PROTEIN 1; UNCOUPLING PROTEIN 2; UNCOUPLING PROTEIN 3; BENZIMIDAZOLE DERIVATIVE; BENZOIC ACID DERIVATIVE; UNCOUPLING PROTEIN;

ADIPOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL STRAIN 3T3; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; ENZYME PHOSPHORYLATION; GENE OVEREXPRESSION; IN VITRO STUDY; IN VIVO STUDY; INTRAABDOMINAL FAT; KNOCKOUT MOUSE; MALE; MOUSE; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROADIPOCYTE; PROTEIN EXPRESSION; RAT; UPREGULATION; WEIGHT GAIN; WILD TYPE; ADIPOCYTE; ADIPOSE TISSUE; ANALYSIS OF VARIANCE; ANIMAL; CELL CULTURE; CELL DIFFERENTIATION; CYTOLOGY; DOSE RESPONSE; DRUG ADMINISTRATION; EATING; FAT INTAKE; FLUORESCENT ANTIBODY TECHNIQUE; GENETICS; METABOLISM; MOUSE MUTANT; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ADIPOCYTES; ADIPOSE TISSUE; ANALYSIS OF VARIANCE; ANIMALS; BENZIMIDAZOLES; BENZOATES; BLOTTING, WESTERN; CELL DIFFERENTIATION; CELLS, CULTURED; DIETARY FATS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; EATING; FLUORESCENT ANTIBODY TECHNIQUE; MICE; MICE, KNOCKOUT; OBESITY; PPAR DELTA; SIGNAL TRANSDUCTION; UNCOUPLING AGENTS; WEIGHT GAIN;

EID: 77950490149     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.109.143958     Document Type: Article

References (41)

1. Kotchen TA. Obesity-related hypertension?: weighing the evidence. Hypertension. 2008. 52. 801-802
2. Kjeldsen SE, Julius S. Hypertension mega-trials with cardiovascular end points: effect of angiotensin-converting enzyme inhibitors and angioten-sin receptor blockers. Am Heart J. 2004;148:747-754.
3. Kurtz TW Beyond the classic angiotensin-receptor-blocker profile. Nat Clin Pract Cardiovasc Med. 2008;5(suppl 1):S19-S26.
4. Andraws R, Brown DL. Effect of inhibition of the renin-angiotensin system on development of type 2 diabetes mellitus (meta-analysis of randomized trials). Am J Cardiol. 2007;99:1006-1012.
5. Araki K, Masaki T, Katsuragi I, Tanaka K, Kakuma T, Yoshimatsu H. Telmisartan prevents obesity and increases the expression of uncoupling protein 1 in diet-induced obese mice. Hypertension. 2006;48:51-57.
6. Di Filippo C, Lampa E, Tufariello E, Petronella P, Freda F, Capuano A, D'Amico M. Effects of irbesartan on the growth and differentiation of adipocytes in obese zucker rats. Obes Res. 2005;13:1909-1914.
7. Furuhashi M, Ura N, Takizawa H, Yoshida D, Moniwa N, Murakami H, Higashiura K, Shimamoto K. Blockade of the renin-angiotensin system decreases adipocyte size with improvement in insulin sensitivity. J Hypertens. 2004;22:1977-1982.
8. Iwai M, Chen R, Imura Y, Horiuchi M. TAK-536, a new AT1 receptor blocker, improves glucose intolerance and adipocyte differentiation. Am J Hypertens. 2007;20:579-586.
9. Kintscher U, Bramlage P, Paar WD, Thoenes M, Unger T. Irbesartan for the treatment of hypertension in patients with the metabolic syndrome: a sub analysis of the Treat to Target post authorization survey: prospective observational, two armed study in 14,200 patients. Cardiovasc Diabetol. 2007;6:12-17.
10. Mori Y, Itoh Y, Tajima N. Angiotensin II receptor blockers downsize adipocytes in spontaneously type 2 diabetic rats with visceral fat obesity. Am J Hypertens. 2007;20:431-436.
11. Shimabukuro M, Tanaka H, Shimabukuro T. Effects of telmisartan on fat distribution in individuals with the metabolic syndrome. J Hypertens. 2007;25:841-848.
12. Zanchi A, Dulloo AG, Perregaux C, Montani JP, Burnier M. Telmisartan prevents the glitazone-induced weight gain without interfering with its insulin-sensitizing properties. Am J Physiol Endocrinol Metab. 2007;293: E91-E95.
13. Zorad S, Dou JT, Benicky J, Hutanu D, Tybitanclova K, Zhou J, Saavedra JM. Long-term angiotensin II AT1 receptor inhibition produces adipose tissue hypotrophy accompanied by increased expression of adiponectin and PPAR γ. Eur J Pharmacol. 2006;552:112-122.
14. Sugimoto K, Qi NR, Kazdova L, Pravenec M, Ogihara T, Kurtz TW. Telmisartan but not valsartan increases caloric expenditure and protects against weight gain and hepatic steatosis. Hypertension. 2006;47: 1003-1009.
15. Erbe DV, Gartrell K, Zhang YL, Suri V, Kirincich SJ, Will S, Perreault M, Wang S, Tobin JF. Molecular activation of PPAR γ by angiotensin II type 1-receptor antagonists. Vascul Pharmacol. 2006;45:154-162.
16. Janke J, Schupp M, Engeli S, Gorzelniak K, Boschmann M, Sauma L, Nystrom FH, Jordan J, Luft FC, Sharma AM. Angiotensin type 1 receptor antagonists induce human in-vitro adipogenesis through peroxisome proliferator-activated receptor-γ activation. J Hypertens. 2006;24: 1809-1816.
17. Schupp M, Clemenz M, Gineste R, Witt H, Janke J, Helleboid S, Hennuyer N, Ruiz P, Unger T, Staels B, Kintscher U. Molecular characterization of new selective peroxisome proliferator activated receptor y modulators with angiotensin receptor blocking activity. Diabetes. 2005; 54:3442-3452.
18. Benson SC, Pershadsingh HA, Ho CI, Chittiboyina A, Desai P, Pravenec M, Qi N, Wang J, Avery MA, Kurtz TW. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPAR γ-modulating activity. Hypertension. 2004;43:993-1002.
19. Schupp M, Janke J, Clasen R, Unger T, Kintscher U. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-7 activity. Circulation. 2004;109:2054-2057.
20. Wang YX, Lee CH, Tiep S, Yu RT, Ham J, Kang H, Evans RM. Peroxisome-proliferator-activated receptor? activates fat metabolism to prevent obesity. Cell. 2003;113:159-170.
21. Yan ZC, Liu DY, Zhang LL, Shen CY, Ma QL, Cao TB, Wang LJ, Nie H, Zidek W, Tepel M, Zhu ZM. Exercise reduces adipose tissue via cannabinoid receptor type 1 which is regulated by peroxisome proliferator-activated receptor-?. Biochem Biophys Res Comm. 2007;354: 427-433.
22. Tanaka T, Yamamoto SI, Asaba H, Hamura H, Ikeda Y, Watanabe M, Magoori K, Ioka RX, Tachibana K, Watanabe Y, Uchiyama Y, Sumi K, Iguchi H, Ito S, Doi T, Hamakubo T, Naito M, Auwerx J, Yanagisaw M, Kodama T, Sakai J. Activation of peroxisome proliferatoractivated receptor? induces fatty acid βoxidation in skeletal muscle and attenuates metabolic syndrome. Proc Natl Acad Sci USA. 2003;100:15924-15929.
23. Barish GD, Narkar VA, Evans RM. PPAR: a dagger in the heart of the metabolic syndrome. J Clin Invest. 2006;116:590-597.
24. Granneman JG, Moore HP. Location, location: protein trafficking and lipolysis in adipocytes. Trends Endocrinol Metab. 2008;19:3-9.
25. Miyoshi H, Perfield JW II, Souza SC, Shen WJ, Zhang HH, Stancheva ZS, Kraemer FB, Obin MS, Greenberg AS. Control of adipose triglycer-ide lipase action by serine 517 of perilipin A globally regulates protein kinase A-stimulated lipolysis in adipocytes. J Biol Chem. 2007;282: 996-1002.
26. Lewis GF, Carpentier A, Adeli K, Giacca A. Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. Endocr Rev. 2002;23:201-229.
27. Carmen GY, Victor SM. Signalling mechanisms regulating lipolysis. Cell Signal. 2006;18:401-408.
28. Miyoshi H, Souza SC, Zhang HH, Strissel KJ, Christoffolete MA, Kovsan J, Rudich A, Kraemer FB, Bianco AC, Obin MS, Greenberg AS. Perilipin promotes hormone-sensitive lipase-mediated adipocyte lipolysis via phosphorylation- dependent and-independent mechanisms. J Biol Chem. 2006;281:15837-15844.
29. Liu DY, Maier A, Scholze A, Rauch U, Boltzen U, Zhao ZG, Zhu ZM, Tepel M. High glucose enhances transient receptor potential channel canonical type 6 dependent calcium influx in human platelets via phos-phatidylinositol 3-kinase dependent pathway. Arterioscler Thromb Vasc Biol. 2008;28:746-751.
30. Zhang LL, Yan Liu D, Ma LQ, Luo ZD, Cao TB, Zhong J, Yan ZC, Wang LJ, Zhao ZG, Zhu SJ, Schrader M, Thilo F, Zhu ZM, Tepel M. Activation of transient receptor potential vanilloid type-1 channel prevents adipogenesis and obesity. Circ Res. 2007;100:1063-1070.
31. Chujo D, Yagi K, Asano A, Muramoto H, Sakai S, Ohnishi A, Shintaku-Kubota M, Mabuchi H, Yamagishi M, Kobayashi J. Telmisartan treatment decreases visceral fat accumulation and improves serum levels of adiponectin and vascular inflammation markers in Japanese hypertensive patients. Hypertens Res. 2007;30:1205-1210.
32. Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P, Anderson C. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:1547-1559.
33. Bath PM, Martin RH, Palesch Y, Cotton D, Yusuf S, Sacco R, Diener HC, Toni D, Estol C, Roberts R. Effect of telmisartan on functional outcome, recurrence, and blood pressure in patients with acute mild ischemic stroke: a PRoFESS Subgroup Analysis. Stroke. 2009;40:3541-3546.
34. Carroll JF, Chiapa AL, Rodriquez M, Phelps DR, Cardarelli KM, Vish-wanatha JK, Bae S, Cardarelli R. Visceral fat, waist circumference, and BMI: impact of race/ethnicity. Obesity. 2008;16:600-607.
35. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, Kravitz BG, Lachin JM, O'Neill MC, Zinman B, Viberti G, for the ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. NEngl JMed. 2007;356:1378-1380.
36. Clemenz M, Frost N, Schupp M, Caron S, Foryst-Ludwig A, Böhm C, Hartge M, Gust R, Staels B, Unger T, Kintscher U. Liver-specific per-oxisome proliferator-activated receptor αtarget gene regulation by the angiotensin type 1 receptor blocker telmisartan. Diabetes. 2008;57: 1405-1413.
37. Flier JS. Obesity wars: molecular progress confronts an expanding epidemic. Cell. 2004;116:337-350.
38. Sanchez RA, Masnatta LD, Pesiney C, Fischer P, Ramirez AJ. Telmisartan improves insulin resistance in high renin nonmodulating salt-sensitive hypertensives. J Hypertens. 2008;26:2393-2398.
39. Benndorf RA, Rudolph T, Appel D, Schwedhelm E, Maas R, Schulze F, Silberhorn E, Böger RH. Telmisartan improves insulin sensitivity in nondiabetic patients with essential hypertension. Metabolism. 2006;55: 1159-1164.
40. Mazzatti DJ, Smith MA, Oita RC, Lim FL, White AJ, Reid MB. Muscle unloading-induced metabolic remodeling is associated with acute alterations in PPAR? and UCP 3 expression. Physiol Genomics. 2008;15:34: 149-161.
41. Brennan KM, Michal JJ, Ramsey JJ, Johnson KA. Body weight loss in beef cows: I-the effect of increased-oxidation on messenger ribonucleic acid levels of uncoupling proteins two and three and peroxisome proliferator activated receptor in skeletal muscle. J Anim Sci. 2009;87:2860-2866.